Section of Molecular Oncologic Pathology, Dept of Molecular Pathology LL2-2, Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic Lerner College of Medicine, 10300 Carnegie Ave, Cleveland, OH 44106;
Am J Clin Pathol. 2013 Nov;140(5):736-46. doi: 10.1309/AJCPJTWK07FSABRJ.
To assess the feasibility of using a novel ultrasensitive bright-field in situ hybridization approach (BRISH) to evaluate κ and λ immunoglobulin messenger RNA (mRNA) expression in situ in B-cell non-Hodgkin lymphoma (NHL).
A series of 110 semiconsecutive clinical cases evaluated for lymphoma with historic flow cytometric (FCM) results were assessed with BRISH.
BRISH light chain restriction (LCR) results were concordant with FCM in 108 (99%) of 109 evaluable cases. Additional small B-cell lymphoma cohorts were successfully evaluated.
BRISH analysis of κ and λ immunoglobulin mRNA expression is a sensitive tool for establishing LCR in B-cell NHL when FCM results are not available.
评估新型超敏明场原位杂交（BRISH）技术评估 B 细胞非霍奇金淋巴瘤（NHL）中κ和λ免疫球蛋白信使 RNA（mRNA）表达的可行性。
对 110 例连续临床淋巴瘤病例进行了 BRISH 检测，这些病例都有历史流式细胞术（FCM）结果。
BRISH 轻链限制（LCR）结果与 109 例可评估病例中的 108 例（99%）FCM 结果一致。还成功评估了其他小 B 细胞淋巴瘤队列。
当 FCM 结果不可用时，BRISH 分析κ和λ免疫球蛋白 mRNA 表达是在 B 细胞 NHL 中建立 LCR 的敏感工具。
